Ad hoc-Mitteilungen
• 20:05 CompuGroup Medical • 18:40 Maternus-Kliniken • 18:00 NYXOAH S.A. • 18:00 Wisekey International • 18:00 ASM International • 17:30 Cargotec B • 16:45 Autobank • 15:30 Suominen • 15:30 Suominen • 15:30 Suominen •
  • Startseite
  • Aktien
  • Nektar Therapeutics Aktie
  • News
  • aktualisieren

    • Nektar Therapeutics News

    22,74 $ -0,13% -0,03 $
    In : 18,660 € | 20:48:08 Uhr Nasdaq | Mehr Kurse »
    WKN: 165417
    ISIN: US6402681083
    US-Symbol: NKTR
    Typ: Aktie
    Jetzt für 0€ handeln

    Nektar Therapeutics News

      
    < Zurück < Zurück
    von 27
    Weiter > Weiter >
    < Zurück < Zurück
    von 27
    Weiter > Weiter >
    15.01.19 - LYNX Analysen
    Das sind die stärksten Aktien des Jahres: Nektar Therapeutics
    Das Jahr 2019 hat gerade erst begonnen, doch an Bewegung an den Aktienmärkten hat es nicht gemangelt.Blickt man auf Einzeltitel ist die Spanne bereits jetzt enorm. Im S&P500 ...  Mehr »
    18.02.21 - PR Newswire
    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
    Nektar to Announce Financial Results for the Fourth Quarter and Year-​Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets PR Newswire
    18.02.21 - PR Newswire
    Thinking about trading options or stock in Nektar Therapeutics, Sleep Number, General Electric, Twilio, or Spirit Airlines?
    Thinking about trading options or stock in Nektar Therapeutics, Sleep Number, General Electric, Twilio, or Spirit Airlines? PR Newswire
    17.02.21 - PR Newswire
    Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder?
    Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder? PR Newswire
    17.02.21 - PR Newswire
    Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with ...
    17.02.21 - PR Newswire
    Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
    Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer Nektar to receive up to $150 million in development funding ...
    01.02.21 - PR Newswire
    Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?
    Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics? PR Newswire
    31.01.21 - The Motley Fool
    3 Aktien, die laut Wall Street 2021 über 50 % steigen werden
    Wall-​Street-Analysten liegen nicht immer richtig. Das sollte man vorweg ganz klar im Kopf haben. Sie werden jedoch dafür bezahlt, jedes Detail über ein bestimmtes Unternehmen ...
    29.01.21 - PR Newswire
    Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp?
    Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp? PR Newswire
    06.01.21 - PR Newswire
    Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
    Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference PR Newswire
    05.01.21 - PR Newswire
    Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development
    Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development PR Newswire
    22.12.20 - PR Newswire
    Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million
    Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million PR Newswire
    15.12.20 - PR Newswire
    Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
    Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck ...
    07.12.20 - PR Newswire
    Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
    Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting PR ...
    11.11.20 - PR Newswire
    Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Nektar Therapeutics Presents New Data from Its Immuno-​Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Updated Clinical Data for ...
    09.11.20 - PR Newswire
    Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
    Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual ...
    05.11.20 - PR Newswire
    Nektar Therapeutics Reports Third Quarter 2020 Financial Results
    Nektar Therapeutics Reports Third Quarter 2020 Financial Results PR Newswire
    04.11.20 - PR Newswire
    New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress
    New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress PR Newswire
    29.10.20 - PR Newswire
    Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress
    Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress PR Newswire
    28.10.20 - PR Newswire
    Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets
    Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets PR Newswire
    27.10.20 - PR Newswire
    Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19
    Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19 Study Designed to Evaluate ...
    < Zurück < Zurück
    von 27
    Weiter > Weiter >

    Newssuche

      

    Videos

      
    14:41 Uhr
    Steuern auf Verluste: "Schlag ins Gesicht der Anleger."
    Hunderttausenden Anlegern drohen möglicherweise Steuern auf Verluste. Das liegt am neuen ... Mehr »